CHSJ

Curr Health Sci J, vol. 49, no. 4, 2023

Immunoexpression of Mismatch Repair Proteins in a Cohort of Colorectal Cancer Patients

[Original Paper]

A.E. Ciobanu(1), C.M. Marginean(2), C. Mesina(3), T.A. Balseanu(4), D. Ciobanu(2), M.M. Florescu(5)


(1)PhD Student, University of Medicine and Pharmacy of Craiova, Romania,
(2)Department of Internal Medicine, University of Medicine and Pharmacy of Craiova, Romania,
(3)Department of Surgery, University of Medicine and Pharmacy of Craiova, Romania,
(4)Center of Clinical and Experimental Medicine, University of Medicine and Pharmacy of Craiova, Romania,
(5)Department of Pathology, University of Medicine and Pharmacy of Craiova, Romania


Abstract:

One of the molecular routes of colorectal carcinogenesis is the lack of mismatch repair (MMR) proteins, which may have substantial clinical consequences in predicting therapy success. This study aimed to analyze the expression of the MutL homolog 1 (MLH1), MutS homolog 2 (MSH2), and MutS homolog 6 (MSH6) in a cohort of 91 colorectal cancer (CRC) patients, and to evaluate the relationship between patient clinicopathological characteristics and immunoexpression of these biomarkers. In this study, we obtained the highest scores of the MLH1 immunoexpression in non-mucinous tumors, moderately differentiated lesions, and in stage IV. The highest values of the MSH2 and MSH6 scores were observed in mucinous tumors, and poorly differentiated lesions, in stages II-III, and stages III-IV, respectively. To improve the stratification criteria for targeted oncological therapy and to predict patient outcomes, markers used may help evaluate the aggressiveness of lesions.


Keywords: Colorectal cancer, adenocarcinoma, mucinous tumors, MMR proteins.



Corresponding: Daniela Ciobanu, Department of Internal Medicine, University of Medicine and Pharmacy of Craiova, Romania, e-mail: elada192@yahoo.com


DOI 10.12865/CHSJ.49.04.11 - Download PDF
current issue cover Download cover
Download contents

Journal archive